Evaluation of the effect of phytosomal curcuminoids on oxidative stress and inflammatory markers in NAFLD: A randomized double-blind placebo-controlled trial. (September 2022)

• Record Type: Journal Article
• Authors: Ali Hosseinian, Seyed; Mehrzad, Jamshid; Reza Mirhafez, Seyed; Saeidi, Jafar; Zhiani, Rahele; Sahebkar, Amirhossein
• Is Part Of: Journal of functional foods. Volume 96(2022)
• Publication Date: 2022-09
• Subjects: Non-alcoholic fatty liver disease -- Curcumin -- Oxidative stress -- Inflammatory markers -- Catalase; Functional foods -- Analysis -- Periodicals; Food -- Biotechnology -- Periodicals; Nutrition -- Periodicals; 613.2
• DOI: 10.1016/j.jff.2022.105202
• Languages: English
• ISSNs: 1756-4646

Abstract

Graphical abstract: Highlights: Non-alcoholic fatty liver disease (NAFLD) is one of the major public health challenges of the 21st century. Oxidative stress (OS) is widely regarded as one of the most important factors in the pathophysiology of this disease. The potential of curcumin in reducing inflammation and oxidative stress has been investigated in many studies. Daily use of phytosomal curcuminoids in patients with NAFLD resulted in a significant increase in CAT activity and a significant reduction in MCP-1. Abstract: Introduction: The aim of this study was to evaluate the effects of the phytosomal curcuminoids on oxidative stress and inflammatory biomarkers along with routine biochemical factors in non-alcoholic fatty liver disease (NAFLD). Methods: Seventy-two patients were selected and randomly divided into Placebo and Curcumin groups (250 mg of phytosomal curcuminoids daily for two months). Biochemical, inflammatory biomarkers including interleukin (IL) 6, IL-10, TNFα (tumor necrosis factor alpha), MCP-1 (monocyte chemoattractant protein-1) and high-sensitivity C-reactive protein (hsCRP) and oxidative stress measurements including malondialdehyde (MDA), superoxide dismutase (SOD) and Catalase (CAT) were measured between two groups before and after the intervention. Results: Curcumin treatment statistically significant increased the activity of CAT enzyme compared with the Placebo group after intervention ( p value = 0.001). However, no significant changes were observed in MDA and SOD biomarkers. Moreover, there was a statistically significant reduction in monocyte chemoattractant protein-1 (MCP-1) levels as a chemokine in the Curcumin group compared with the Placebo group after treatment ( p value = 0.007). Conclusion: Daily use of 250 mg of phytosomal curcuminoids for two months in patients with NAFLD resulted in a significant increase of CAT activity and a significant reduction of MCP-1.